UCLA's New $10 COVID Test Can Process Tens of Thousands of Results in a Day

UCLA's New $10 COVID Test Can Process Tens of Thousands of Results in a Day

The University of California, Los Angeles received U.S. Food & Drug Administration approval Wednesday for a new novel coronavirus testing method that is faster and cheaper than most on the market, allowing for thousands of tests to be processed and their results returned in a day.

The test analyzes the genomic sequencing of samples to identify infected people — including those who are asymptomatic — by having them spit into a tube that then goes directly into a machine.


The test uses saliva without extracting the RNA from it, and so is "accurate enough" in comparison to the traditional polymerase chain reaction — or PCR — tests, which are the existing gold-standard for testing but can take days to process, said Dr. Eleazar Eskin, a computer scientist and geneticist who is chair of the Department of Computational Medicine at UCLA. He was part of the team that developed the new testing technology.

The researchers who developed the method hope to test the entire UCLA population twice a week beginning in a few weeks and already have a proof-of-concept online, Eskin said.

The platform known as "SwabSeq" looks for a piece of the genetic code of SARS-CoV-2, an RNA virus that causes COVID-19. For every sample of saliva received, the researchers add a barcode or "sticker." They then mix the samples together and put them into the genomic sequencing machine. Then, by looking at the barcode or "sticker" of the result, they can identify those samples infected with the novel coronavirus.

At scale, "it costs $10 a test, and we can do tens of thousands of tests at UCLA with a lab of 10 people," Eskin said. The technology leverages decades of advancements in genomic sequencing technology since mapping of the Human Genome Project.

According to a pre-print article on the technology, which has not been peer reviewed, the researchers wrote: "SwabSeq is simple, sensitive, flexible, rapidly scalable, inexpensive enough to test widely and frequently, and can provide a turn around time of 12 to 24 hours."

The traditional PCR tests are far more labor intensive and require extracting the RNA from a patient's sample under a specific safety hood before they can be tested.

"We literally have people spit into a tube and that tube goes directly in the machine," Eskin said. "So it's going to be much more scalable."

The sample goes into a sequencer and then put onto a computer to analyze the data.

SwabSeq was developed as part of a collaboration between UCLA's Department of Human Genetics, the university's new Department of Computational Medicine, UCLA Health and Octant Inc., a startup biotechnology company founded and incubated at UCLA. The group began working on the new method in March, Eskin said.___

__

Do you have a story that needs to be told? My DMs are open on Twitter @latams. You can also email me at tami(at)dot.la, or ask for my contact on Signal, for more secure and private communications.

Subscribe to our newsletter to catch every headline.

Minutes into filling out my absentee ballot last week, I was momentarily distracted by my dog Seamus. A moment later, I realized in horror that I was filling in the wrong bubble — accidentally voting "no" on a ballot measure that I meant to vote "yes" on.

It was only a few ink marks, but it was noticeable enough. Trying to fix my mistake, I darkly and fully filled in the correct circle and then, as if testifying to an error on a check, put my initials next to the one I wanted.

Then I worried. As a reporter who has previously covered election security for years, I went on a mini-quest trying to understand how a small mistake can have larger repercussions.

As Los Angeles County's 5.6 million registered voters all receive ballots at home for the first time, I knew my experience could not be unique. But I wondered, would my vote count? Or would my entire ballot now be discarded?

Read more Show less

Fiction Riot, the L.A.-based entertainment company behind mobile streaming app Ficto, raised $250,000 this week. Chief executive Mike Esola says the company has intentionally grown slowly, eschewing venture capital in favor of incremental fundraising from family offices, institutions and friends and family.

Read more Show less
RELATEDEDITOR'S PICKS

Trending